Drug intelligence / Profile preview

SA016

Development stage: Preclinical
Lead developer: Suzhou Siran Biotech
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

SA016 is a small interfering RNA (siRNA) therapeutic candidate being developed by Suzhou Siran Biotechnology (SiranBio) for the treatment of hypertension. As an siRNA, it is designed to silence the expression of a specific, though currently undisclosed, gene involved in the regulation of blood pressure. Preclinical data demonstrating the efficacy and safety of SA016 were presented at the CRT2024 Conference. The drug utilizes SiranBio's proprietary siRNA delivery and modification platforms, which are designed to optimize tissue targeting and stability. It is currently in the preclinical stage of development.

Beyond the preview

Go deeper on SA016.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SA016.

Explore the full profile